tirzepatide patent expiry 2036 eli lilly Looming GLP-1 drug expirations draw generics firms The Heavy Price of GLP-1

Special population dosing modifications Standard dose charts assume otherwise healthy adults with obesity

This has joined industry criticism from heavyweights like George Yancopoulos, a co-founder of Regeneron, who suggested that blockbuster weight-loss drugs could cause more harm than good in the Financial Times last October

Medicare coverage for weight-loss-only use has historically been limited, and readers should confirm current benefits directly with their plan

In the UK, prescribing decisions are guided by the specific licensed indication, patient preference, clinical circumstances, and local formulary recommendations